London, UK; Brentwood, TN, US: 13 August 2007 - Protherics PLC ("Protherics" or the "Company"), the international biopharmaceutical company focused on critical care and cancer, announces that Rolf Soderstrom, who was appointed as Finance Director of the Company on 10 August 2007, has been granted options to subscribe for 423,076 ordinary shares in the Company under the terms of the Company's Long-Term Incentive Plan. The options were granted on 10 August 2007 and are exercisable between the third and tenth anniversary of the date of grant at a price of 2p per ordinary share, subject to the achievement of performance conditions.
